Physician

Darren Sigal, MD

According to 2025 Medicare claims, Darren Sigal, MD (NPI: 1417120080) practices hematology/oncology in the San Diego-Chula Vista-Carlsbad, CA market, with the plurality of this provider's patient population coming from San Diego, CA. This provider's primary affiliated billing organization is SCRIPPS HEALTH (NPI: 1275899072; TIN: 232380812) and primary practice location at 92037-1027. Sigal is affiliated with the Scripps Accountable Care Organization, LLC (ACO ID: A3521), participating under the MSSP model.

Sigal's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 816 traditional Medicare patients, billed 329,468 HCPCS/CPT codes, and received $4,318,099 in Medicare payments. The top billing code was 96413 (Administration of chemotherapy into vein, 1 hour or less). Part D data shows 1,205 prescription claims across 187 beneficiaries totaling $671,013 in drug costs, led by Creon (Lipase/Protease/Amylase). DME data shows 68 claims. Open Payments data shows 39 records totaling $56,426. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved from a lower plateau to a higher plateau, from $1,352,445 to $4,318,099. Concurrently, Part D prescription costs have moved up and down with repeated peaks and valleys, starting at $1,002,130 and ending at $671,013. In contrast, DME billing represents a smaller volume and started with an early spike, then settled into a lower baseline, moving from $16,446 to $1,629.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	582	101,963	$1,352,445
2016	621	127,767	$1,699,661
2017	643	160,869	$2,301,929
2018	539	155,500	$2,475,120
2019	584	167,959	$2,619,665
2020	524	225,624	$3,436,664
2021	520	184,102	$3,449,505
2022	547	219,838	$3,697,933
2023	596	234,909	$3,931,828
2024	816	329,468	$4,318,099

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	164	762	$1,002,130
2016	163	668	$906,649
2017	188	824	$911,731
2018	216	1,141	$895,865
2019	231	1,264	$893,641
2020	221	1,346	$858,368
2021	189	900	$637,232
2022	237	1,362	$1,333,252
2023	220	1,213	$1,044,867
2024	187	1,205	$671,013

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	65	316	$100,663
2016	N/R	144	$46,172
2017	12	124	$29,751
2018	49	161	$20,950
2019	22	76	$7,989
2020	N/R	15	$2,846
2021	N/R	N/R	N/R
2022	29	110	$3,494
2023	N/R	104	$55,967
2024	N/R	68	$1,721

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
96413	Administration of chemotherapy into vein, 1 hour or less	198	887	$117
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	359	1,460	$105
96365	Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less	195	282	$55
96375	Injection of additional new drug or substance into vein	178	1,795	$14
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	275	772	$13

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Creon	Lipase/Protease/Amylase	71	2,695	$210,465
Everolimus	Everolimus	23	702	$44,761
Eliquis	Apixaban	50	2,280	$42,866
Prochlorperazine Maleate	Prochlorperazine Maleate	165	2,443	$2,599
Dexamethasone	Dexamethasone	145	4,157	$2,093

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J8521	Capecitabine, oral, 500 mg	N	N/R	20	$866
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	20	$376
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	16	$364
J8520	Capecitabine, oral, 150 mg	N	N/R	12	$114

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	38	$18,537	PFIZER INC.
Research Payments	Reported research-related payment or transfer-of-value amount.	1	$37,889	AstraZeneca UK Limited
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Darren Sigal, MD?

Tedicare shows public-source Medicare data for Darren Sigal, MD (NPI 1417120080), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Darren Sigal, MD have ACO affiliation data?

Darren Sigal, MD is shown with ACO affiliation data for Scripps Accountable Care Organization, LLC (MSSP, ACO ID A3521).

What billing organization is linked to Darren Sigal, MD?

Darren Sigal, MD is linked to SCRIPPS HEALTH (billing NPI 1275899072) in the available physician profile data.

Does Darren Sigal, MD have Open Payments data?

Darren Sigal, MD has 39 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.